Miraflores, Peru Clinical Trials

A listing of Miraflores, Peru clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 96 clinical trials
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

measurable disease
advanced cancer
cancer
cancer of the ovary
mk-3475
Oncosalud ( Site 3200)
 (1.5 away) Contact site
  • 19 views
  • 12 Sep, 2021
  • +150 other locations
A Phase 2b Diabetic Kidney Disease Study

A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease

nephropathy
diabetic nephropathy
Research Site
 (1.0 away) Contact site
  • 54 views
  • 14 Aug, 2021
  • +115 other locations
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal Pancreatic or Colorectal Cancer

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer

Research Site
 (1.5 away) Contact site
  • 143 views
  • 03 Sep, 2021
  • +192 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Overall Survival (OS) and Event-free Survival (EFS) in: participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors express …

external radiation
oxaliplatin
carcinoma
mk-3475
pembrolizumab
Instituto Nacional de Enfermedades Neoplasicas ( Site 0141)
 (2.5 away) Contact site
  • 32 views
  • 15 Sep, 2021
  • +152 other locations
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma. Hypotheses include: Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response …

measurable disease
oropharyngeal
caries
cancer
mk-3475
Instituto Nacional de Enfermedades Neoplasicas ( Site 0701)
 (2.5 away) Contact site
  • 15 views
  • 15 Sep, 2021
  • +150 other locations
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Ovarian Cancer or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy

Research Site
 (1.5 away) Contact site
  • 5 views
  • 28 Aug, 2021
  • +174 other locations
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Study MO39874 is an open-label, phase IIIb, single arm, multicenter study conducted in participants with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not received chemotherapy for their unresectable locally advanced or metastatic disease.

measurable disease
paclitaxel
programmed cell death 1 ligand 1
breast cancer
metastasis
Instituto Nacional de Enfermedades Neoplasicas
 (2.5 away) Contact site
  • 147 views
  • 15 Sep, 2021
  • +163 other locations
Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

Novartis Investigative Site
 (6.0 away) Contact site
  • 143 views
  • 15 Sep, 2021
  • +558 other locations
Evaluating Newly Approved Drugs for Multidrug-resistant TB

endTB Clinical Trial a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB).

moxifloxacin
delamanid
clofazimine
pyrazinamide
bedaquiline
Socios En Salud
 (4.5 away) Contact site
  • 223 views
  • 15 Sep, 2021
  • +7 other locations
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

This is a Phase 1b/2, multi-center study in which patients will receive KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).

antinuclear antibody
prednisone
adrenaline
mycophenolic acid
leflunomide
KZR Research Site
 (8.0 away) Contact site
  • 261 views
  • 08 Sep, 2021
  • +52 other locations